Correction to Lancet Oncol 2019; 20: 1750–59

{"title":"Correction to Lancet Oncol 2019; 20: 1750–59","authors":"","doi":"10.1016/s1470-2045(25)00014-2","DOIUrl":null,"url":null,"abstract":"<em>Park YH, Kim T-Y, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.</em> Lancet Oncol <em>2019; <strong>20:</strong> 1750–59</em>—In this Article, in the Outcomes section of the Methods, it was stated incorrectly that progression-free survival and overall survival were measured from randomisation, whereas they were actually measured from day 1 of cycle 1. This was also incorrect in the Results section and on the x-axis title of figure 2. These corrections have been made to the online version as of Feb 3, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"77 2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(25)00014-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Park YH, Kim T-Y, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019; 20: 1750–59—In this Article, in the Outcomes section of the Methods, it was stated incorrectly that progression-free survival and overall survival were measured from randomisation, whereas they were actually measured from day 1 of cycle 1. This was also incorrect in the Results section and on the x-axis title of figure 2. These corrections have been made to the online version as of Feb 3, 2025.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
柳叶刀- Oncol 2019更正;20: 1750 - 59
朴玉辉,金天珧,金GM,等。帕博西尼、依西美坦联合促性腺激素释放激素激动剂与卡培他滨在激素受体阳性、her2阴性转移性乳腺癌(KCSG-BR15-10)绝经前妇女中的对比:一项多中心、开放标签、随机、2期试验。柳叶刀肿瘤学2019;[20:17 50 - 59]在这篇文章中,在方法的结果部分,错误地指出无进展生存期和总生存期是从随机化开始测量的,而它们实际上是从周期1的第一天开始测量的。这在Results部分和图2的x轴标题中也是不正确的。这些更正已于2025年2月3日对在线版本进行了修改。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Towards response-adapted neoadjuvant breast cancer treatment Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study France plans national targeted lung cancer screening
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1